All sponsors

ImmunityBio, Inc. $IBRX

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS15
PHASE 3 / 2-32
RECRUITING6
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO58%

Delay Index: of 12 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +8.0 months). See all sponsors →

Open ImmunityBio, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
N-803 and BCG
NCT03022825
P2/3Active, not recruitingBladder Cancer1902024-10-01 (+70 mo)
N-803
NCT04390399
P2Active, not recruitingPancreatic Cancer3282025-10-13 (+29 mo)
BCG (50mg/instillation) + N-803 (400 μg/instillation)
NCT02138734
P1/2Active, not recruitingNon-muscle Invasive Bladder Cancer3692026-09-30 (+101 mo)
INTERRUPT_LC
NCT07108036
P2RecruitingLong COVID202026-10 (+2 mo)
N-803 and BCG
NCT06829823
P2Not yet recruitingNon-muscle Invasive Bladder Cancer (NMIBC)202026-11 (+6 mo)
Anktiva
NCT07123727
P2RecruitingLong COVID; Long COVID Syndrome402027-03 (+8 mo)
Gemcitabine
NCT06710288
P2RecruitingPlatinum-resistant Ovarian Cancer202027-05
CD19 t-haNK- IV Administration
NCT07125872
P2RecruitingRelapsed B-Cell Non Hodgkin Lymphoma202027-05-25
CD19 t-haNK- IV Administration
NCT07477366
P2Not yet recruitingRelapsed B-Cell Non-Hodgkin Lymphoma202027-12
Intravesical Recombinant Mycobacterium (rMBCG)
NCT06800963
P1/2RecruitingNMIBC402028-02
Nogapendekin alfa inbakicept (NAI)
NCT07783789
P2Not yet recruitingSepsis502028-05-12
N-803
NCT06745908
P3RecruitingNSCLC Stage IV5072028-09
N-803 + Pembrolizumab
NCT03228667
P2Active, not recruitingNon-Small Cell Lung Cancer; Small Cell Lung Cancer402029-08-31 (+108 mo)
Bevacizumab
NCT06061809
P2Active, not recruitingGlioblastoma342029-12-31 (+12 mo)
Nogapendekin Alfa Inbakicept (NAI)
NCT07628062
P2Not yet recruitingHPV-Positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma702030-12-31